JPMorgan Chase & Co. Decreases Stake in Krystal Biotech, Inc. $KRYS

JPMorgan Chase & Co. lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 91,153 shares of the company’s stock after selling 9,621 shares during the quarter. JPMorgan Chase & Co.’s holdings in Krystal Biotech were worth $12,530,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D boosted its holdings in shares of Krystal Biotech by 45.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares during the period. EP Wealth Advisors LLC purchased a new position in Krystal Biotech during the 1st quarter valued at about $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after purchasing an additional 365,304 shares during the last quarter. S Squared Technology LLC lifted its holdings in Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock worth $17,528,000 after buying an additional 2,000 shares during the period. Finally, Tempus Wealth Planning LLC purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $327,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.70% of the company’s stock.

Krystal Biotech Trading Up 5.5%

Shares of KRYS stock opened at $234.13 on Monday. The company’s fifty day moving average price is $197.92 and its 200-day moving average price is $162.98. The stock has a market cap of $6.79 billion, a PE ratio of 35.10 and a beta of 0.48. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $234.65.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on KRYS. HC Wainwright reissued a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Citigroup boosted their price objective on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 1st. Finally, Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).